Corporate Action Notice

June 23, 2015

Reverse Split

Direct Line Insurance

DR CUSIP: 25490E103 / DR ISIN: US25490E1038

DR Ticker Symbol: DIISY

Ratio: (DS: Underlying Share): 1:4

Please be advised that Direct Line Insurance has announced a Share Consolidation of eleven new shares for every twelve existing shares as of the local record date of June 29, 2015.

As a result, BNY Mellon will affect a reverse stock split on the Direct Line Insurance Depositary Receipt ("DR") program. Effective June 30, 2015, DR holders of Direct Line Insurance are required on a mandatory basis to surrender their DR(s) for cancellation and exchange their "Old" DRs (CUSIP 25490E103) for "new" DRs (CUSIP 25490E202). DR holders will receive 11 "New" Depositary Shares ("DSs") (CUSIP 25490E202) for every 12 "Old" DSs (CUSIP 25490E103). Only whole DSs will be distributed. BNY Mellon will attempt to sell any fractional DSs and distribute the cash proceeds to DR holders.

BNY MELLON HAS ESTABLISHED THE FOLLOWING DATES FOR THIS CORPORATE ACTION:

Effective Date: June 30, 2015
Exchange Rate: 11 new DS for 12 old DSs
New CUSIP: 25490E202

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

NEW YORK

Ravi Davis Richard J Maehr + 1 212 815 2267 DRdesk@bnymellon.com LONDON

Damon Rowan Vice President + 44 207 163 7511 damon.rowan@bnymellon.com HONG KONG

Herston Powers Vice President + 852 2 840 9868

herston.powers@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon as depositary may use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. The corporate action details are provided for informational purposes only. BNY Mellon does not warrant or guarantee the accuracy or completeness, and does not undertake any obligation to update or amend, this information or data. We provide no advice, recommendation or endorsement with respect to any company or security. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

